Pharmacoeconomics of dapagliflozin in patients with type 2 diabetes mellitus with inadequate glycemic control
Objectives. To evaluate the cost-effectiveness of dapagliflozin in combination with metformin in the treatment T2DM in comparison with glimepiride and sitagliptin also combined with metformin. Methods. Cost-utility analysis, discounting and economic feasibility assessment were performed. The results...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Book |
| Published: |
Izdatelstvo OKI,
2018-06-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Objectives. To evaluate the cost-effectiveness of dapagliflozin in combination with metformin in the treatment T2DM in comparison with glimepiride and sitagliptin also combined with metformin. Methods. Cost-utility analysis, discounting and economic feasibility assessment were performed. The results are expressed in QALY and ICUR. Pharmacoeconomic analysis showed that the application of the strategy of treatment: metformin + dapagliflozin vs metformin + sitagliptin provided 9.83 and 9.82 QALYs respectively, and the ICUR - 341.413 rubles; metformin + dapagliflozin vs metformin + glimepiride provided 9.82 and 9.47 QALY respectively, and the ICUR - 145.213 rubles. The use of combination therapy metformin + dapagliflozin is economically acceptable treatment strategy compared with combination therapy with metformin + sitagliptin and metformin + glimepiride, as ICUR indicators for dapagliflozin + metformin therapy did not exceed the cost-effectiveness threshold - «willingness to pay ratio» for Russia in any of the compared treatment strategies. Conclusion. Combination therapy metformin + dapagliflozin for treating T2DM provide good value for money for Russian state reimbursement system. |
|---|---|
| Item Description: | 2588-0519 2618-8473 |